Postmenopausal Osteoporosis Clinical Trial
Official title:
Tainan Hospital, Ministry of Health and Welfare, Taiwan
Osteoporosis weakens bones with age, increasing fracture risk. Exercise improves physical function and reduces falls, crucial for preventing osteoporotic fractures, especially with balance, resistance, and multi-component training. Agility exercise, integrating various aspects like aerobic, strength, balance, and cognitive tasks, is promising for fall prevention in older adults, though its effectiveness in osteoporosis is not extensively studied. This study compares agility and resistance exercise impacts on physical function and balance stability in postmenopausal osteoporosis. Fifty-one women (average age: 68±6.3y, BMI: 22.3±2.7 kg/m2) were divided into agility exercise (AG), resistance exercise (RG), and control groups (CG) through purposive sampling. AG and RG received added intervention training once a week for 2 hours over 12 weeks. Main outcomes included physical function and balance stability measured through various tests.
Main activities of agility training group (AG): Use rope ladders and cones to perform multiple tasks of direction changes, acceleration and deceleration of footsteps, hand and foot coordination and spatial orientation training. Main activities of resistance training group (AG): Resistance training for upper and lower limb muscles and core muscles, including squats, use of elastic bands, and simple bars. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05902078 -
Eldecalcitol and Calcitriol in Postmenopausal Women With Low Bone Mineral Density or Mild Osteoporosis
|
Phase 4 | |
| Completed |
NCT05087030 -
Comparative Efficacy and Safety Study of RGB-14-P and Prolia® in Women With Postmenopausal Osteoporosis
|
Phase 3 | |
| Completed |
NCT01544894 -
Clinical Study of Raloxifene and Strontium Ranelate in Postmenopausal Osteoporosis
|
Phase 4 | |
| Completed |
NCT00377819 -
Study of Transitioning From Alendronate to Denosumab
|
Phase 3 | |
| Completed |
NCT00381251 -
Study Comparing Bioequivalence of Two New Formulations of Premarin/MPA With Premarin/MPA Reference Formulation.
|
Phase 1 | |
| Completed |
NCT00239629 -
Teriparatide and Strontium Ranelate Head-To-Head Comparison Trial
|
Phase 4 | |
| Completed |
NCT04026256 -
Bone Modeling Effects of Combined Anabolic/Antiresorptive Administration
|
Phase 4 | |
| Terminated |
NCT00529373 -
A Study of MK-0822 in Postmenopausal Women With Osteoporosis to Assess Fracture Risk (MK-0822-018)
|
Phase 3 | |
| Completed |
NCT00092014 -
A Study to Evaluate and Compare Alendronate and Risedronate on Bone Mineral Density in Women With Postmenopausal Osteoporosis (MK-0217-211)
|
Phase 3 | |
| Recruiting |
NCT06079476 -
A Study of Romosozumab (EVENITY®) in Postmenopausal Women in India With Osteoporosis at a High Risk of Fracture.
|
Phase 4 | |
| Not yet recruiting |
NCT04719650 -
Clinical Pharmacokinetics and Pharmacodynamics Study of Different Doses of Zoledronic Acid
|
Phase 4 | |
| Recruiting |
NCT02981732 -
CLCF1 Gene Associated With Postmenopausal Osteoporosis of Kidney Yin Deficiency Syndrome
|
N/A | |
| Completed |
NCT01709110 -
VERtebral Fracture Treatment Comparisons in Osteoporotic Women
|
Phase 4 | |
| Completed |
NCT01348243 -
Efficacy Of Clodronate 200 Mg/4 Ml I.M. Solution With 1% Lidocaine Every Other Week Vs Clodronate 100 Mg/3,3ml I.M. Solution With 1% Lidocaine Once-Week In A 1-Year Treatment Period Of Women With Postmenopausal Osteoporosis
|
Phase 3 | |
| Completed |
NCT00541658 -
A Study of a 35 mg Delayed Release Formulation of Risedronate for Osteoporosis
|
Phase 3 | |
| Completed |
NCT00395395 -
Effects of Water and Food Intake on the Pharmacokinetics and Pharmacodynamics of Oral Salmon Calcitonin in Healthy Postmenopausal Women
|
Phase 1 | |
| Completed |
NCT00247273 -
A Study of Monthly Risedronate for Osteoporosis
|
Phase 3 | |
| Active, not recruiting |
NCT03720886 -
G56W1 in Women With Postmenopausal Osteoporosis
|
Phase 1/Phase 2 | |
| Completed |
NCT01668589 -
Observational Study of Denosumab (Prolia®) in Postmenopausal Women With Osteoporosis
|
N/A | |
| Completed |
NCT04664959 -
A Study to Compare SB16 (Proposed Denosumab Biosimilar) to Prolia® in Postmenopausal Women With Osteoporosis
|
Phase 3 |